Netherlands· NL-47a9cbc4c063
Brineura 150 mg oplossing voor infusie
A cerliponase alfa product containing cerliponase alfa, registered in Netherlands by BioMarin International Limited. The same ATC class is registered in 10 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Cerliponase alfa is registered in 10 of 19 countries.
Countries holding a registration under ATC A16AB17 (cerliponase alfa), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Cerliponase alfa · ATC A16AB17
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CERLIPONASE ALFA
- Manufacturer
- BioMarin International Limited
- Country
- Netherlands (NL)
- ATC code
- A16AB17
- ATC class
- Cerliponase alfa
- Defined daily dose
- 21 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/17/1192
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cerliponase alfa in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBrineura 150 mgBioMarin International
- CzechiaBRINEURABioMarin International Limited, Dublin
- SpainBRINEURA 150 MG SOLUCION PARA PERFUSIONBiomarin International Limited
- FinlandBrineuraBiomarin International Limited
- FranceBRINEURA 150 mg, solution pour perfusionBIOMARIN INTERNATIONAL LIMITED (IRLANDE)
- IrelandBrineura 150 mg solution for infusionBioMarin International Limited
- IcelandBrineuraBioMarin International Limited
- SwedenBrineura 150 mg Infusionsvätska, lösningBioMarin International Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Brineura
- Liechtenstein · Brineura
- Norway · Brineura
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0ae6f339-3dfc-4405-ab1e-6948979dc62f GET /v1/drugs/0ae6f339-3dfc-4405-ab1e-6948979dc62f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor infusie",
"route": "Intracerebraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/brineura-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Cerliponase alfa",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp119521",
"excipients": [
"CALCIUMCHLORIDE 2-WATER (E 509)",
"CALCIUMCHLORIDE 2-WATER (E 509)",
"DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
"DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
"KALIUMCHLORIDE (E 508)",
"KALIUMCHLORIDE (E 508)",
"MAGNESIUMCHLORIDE 6-WATER (E 511)",
"MAGNESIUMCHLORIDE 6-WATER (E 511)",
"NATRIUMCHLORIDE",
"NATRIUMCHLORIDE",
"NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
"NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
"WATER VOOR INJECTIE",
"WATER VOOR INJECTIE"
],
"substances": [
"CERLIPONASE ALFA"
],
"leaflet_url": null,
"authorised_at": "2017/05/30",
"procedure_number": "EMEA/H/C/004065",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/17/1192",
"additional_monitoring": "Y"
}See everything about cerliponase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.